FDA approves brain tumor warning on Depo-Provera label

Taking stock of the drug industry, from the lab to the medicine chest

December 17, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

adobe STAT+ | FDA approves brain tumor warning on Depo-Provera label as court battle grows over side effects The move comes as Pfizer is locked in a high-profile court battle with nearly 2,000 women, who claim the company knew about the cancer risk. By Ed Silverman STAT+ | Meta is urged by state attorneys general to boost enforcement of weight-loss drug advertising The state attorneys general also want the company to take additional measures to prevent AI-generated content in the ads. By Ed Silverman STAT+ | More drugmakers set to sign pricing deals with Trump on Friday Pharma companies have agreed to lower prices and invest in the U.S. in exchange for avoiding tariffs and benefits like faster drug reviews. By Daniel Payne Hyacinth Empinado/STAT STAT+ | The Worst Biopharma CEO of 2025 made decisions with tragic consequences Ingram has taken on unnecessary risks for Duchenne patients, and hasn't served biotech investors well either. By Adam Feuerstein Opinion: We crunched the numbers on drug discovery in the U.S. vs. China. The results were alarming Federal policy and priorities are kneecapping the historical American engines of innovation, to China's benefit. By Michael Kinch and Kevin Gardner

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser